History
A list of downloadable documents created during development.
Background information
-
-
Appendix A: Decision paper considered by the Institute's Guidance Executive
-
Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 89 KB)
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 79 KB)
Colorectal cancer (metastatic) - bevacizumab & cetuximab: appeal
-
Colorectal cancer (metastatic) - bevacizumab & cetuximab: appeal information
-
Appeal announcement: Bevacizumab and cetuximab for metastatic colorectal cancer information
-
Appeal received from Merck Pharmaceuticals
-
Initial scrutiny letter
-
-
Merck Pharmaceuticals response to the scrutiny letter
-
Merck Pharmaceuticals response to the scrutiny letter (PDF 127 KB)
-
Appeals received
-
Merck Pharmaceuticals 1
-
-
Merck Pharmaceuticals 2
-
-
Appeal received from Bowel Cancer UK and Cancerbackup (joint appeal)
-
Appeals received
-
-
Initial scrutiny letter
-
-
Bowel Cancer UK & Cancerbackup's response to the scrutiny letter
-
Bowel Cancer UK & Cancerbackup's response to the scrutiny letter (PDF 72 KB)
-
Final Scrutiny letter
-
-
Colorectal cancer (metastatic) - bevacizumab & cetuximab: Appeal panel decision
-
Colorectal cancer (metastatic) - bevacizumab & cetuximab: Appeal panel decision (PDF 43 KB)
Colorectal cancer (metastatic) - bevacizumab & cetuximab - Final appraisal determination
-
Colorectal cancer (metastatic) - bevacizumab & cetuximab - Final appraisal determination information
-
Final appraisal determination
-
-
Response to consultee and commentator comments and response to public and web comments on the ACD
-
-
Consultee and commentator comments on the ACD
-
Royal College of Physicians
-
-
Royal College of Pathologists
-
-
Royal College of Nursing
-
-
Roche Products Ltd
-
-
NHS Quality Improvement Scotland
-
-
Merck Pharmaceuticals
-
-
Cancer Backup
-
-
Bowel Cancer UK
-
-
Anthoney
-
Colorectal cancer (advanced) - bevacizumab & cetuximab (appraisal consultation document)
Overview
-
Overview
-
Colorectal cancer (metastatic) - bevacizumab & cetuximab: Assessment report
-
Colorectal cancer (metastatic) - bevacizumab & cetuximab: Assessment report
-
Colorectal cancer (metastatic) - bevacizumab & cetuximab: Assessment report (PDF 1.11 MB)
Consultee and commentator comments on the assessment report
-
Consultee and commentator comments on the assessment report
-
Bowel Cancer UK
-
-
Merck Pharmaceuticals
-
-
NHS Quality Improvement Scotland
-
-
Roche
-
-
Royal College of Nursing
-
-
Royal College of Pathologists
-
Non-manufacturer submissions
-
Non-manufacturer submissions
-
Association of Coloproctologists of Great Britain
-
Association of Coloproctologists of Great Britain (PDF 326 KB)
-
Beating Bowel Cancer
-
-
Bowel Cancer UK (formerly known as Colon Cancer Concern)
-
Bowel Cancer UK (formerly known as Colon Cancer Concern) (PDF 2.02 MB)
-
Cancerbackup
-
-
Royal College of Nursing
-
-
Royal College of Pathologists
-
-
Royal College of Physicians (support letter)
-
Assessment groups response to comments on the assessment report
-
ScHARR
-
Manufacturer submissions
-
Manufacturer submissions
-
Roche
-
-
Merck
-
Expert written personal statements
-
Expert written personal statements
-
Anthoney
-
-
Rhys Evans
-
-
Smith
-
Final protocol
-
Final protocol
-
Summary of comments on the draft scope
-
Summary of comments on the draft scope
-
Final scope
-
Final scope
-
Archive: Draft scope
-
Archive: Draft scope
-
Summary of comments on the provisional matrix of consultees and commentators
-
Summary of comments on the provisional matrix of consultees and commentators
-
Summary of comments on the provisional matrix of consultees and commentators (PDF 20 KB)
Archive: Provisional matrix of consultees and commentators
-
Archive: Provisional matrix of consultees and commentators
-
Archive: Provisional matrix of consultees and commentators (PDF 29 KB)